Vaccine (and Other Biologic) Manufacturing Services for Infectious Diseases

The National Institutes of Health (NIH) has issued a forecast for a contract focused on manufacturing services related to vaccines and other biologics targeting infectious diseases. This contract, classified under NAICS code 541714, is intended to secure expertise and capacity for the production of biologic products that address public health needs involving infectious agents. The contract is still in the forecast stage, with details such as solicitation number and place of performance not yet specified, indicating an early phase in the acquisition process. The NIH aims to engage qualified organizations capable of delivering specialized manufacturing services that will support vaccine development efforts. Key points of contact for this contract include Lisa Wei, the program point of contact, and Andy Cherry, the contracting officer, who can provide further information as the process moves forward. The forecast suggests an emphasis on strengthening infrastructure for biologic manufacturing to better respond to emerging infectious disease threats, aligning with the NIH’s mission of advancing health research and preparedness.